at 007

AT-007 is an orally active CNS penetrant Aldose Reductase inhibitor for the treatment of Galactosemia (IC50: 100 pM). It reduces toxic galactitol levels and prevents disease complications in GALT deficiency rats.

Compound V007-6018 is a pharmaceutical compound used for drug screening.

NCC007 is a novel CKIα and CKIδ dual inhibitors by structural modification of N9 and C2 position of longdaysin.

KBC-007 is a synthetic branched chain-containing analog of α-galactosylceramide (α-GalCer). It induces IL-4 and IFN-γ secretion by mouse splenocytes when used at a concentration of 0.5 ng/ml and IL-2 secretion by DN32.D3 NKT hybridoma cells co-cultured with CD1d-transfected RBL cells pre-loaded with KBC-007 at a concentration of 8 ng/ml. KBC-007 (1 μg per animal) increases levels of IL-4, but not IFN-γ, to a similar degree as α-GalCer in mouse serum. KBC-007 (0.5 μg per animal) increases the survival rate of mice immunized with the inactivated influenza A virus A/PR/8/34 in a model of influenza infection.

Compound N007-0024 is a useful organic compound for research related to life sciences and the catalog number is T131370.

Compound N007-0023 is a useful organic compound for research related to life sciences and the catalog number is T131371.

Compound N007-0014 is a useful organic compound for research related to life sciences and the catalog number is T131372.

LZ-007 is an agonist of the Farnesoid X receptor (FXR), with an EC50 of 51 nM as determined by TR-FRET assay, and an EC50 of 76 nM in HepG2 cells. It exhibits favorable pharmacokinetic properties in SD rats and can improve metabolic dysfunction-associated steatohepatitis induced by high-fat diets and CCl4 in mice.

ALT-007 is an orally bioavailable inhibitor of serine palmitoyltransferase (SPT), the rate-limiting enzyme in de novo ceramide synthesis. In murine models of age-related sarcopenia, ALT-007 effectively restores muscle mass and function impaired by aging. Additionally, ALT-007 may enhance protein homeostasis in Caenorhabditis elegans and in mouse models of aging and age-associated diseases, acting as a ceramide inhibitor.

JHW 007 hydrochloride is a Dopamine uptake inhibitor.

TFC-007 is a selective and efficient hematopoietic prostaglandin D synthase (H-PGDS) inhibitor, suppressing inflammatory factors. It can be used to synthesize H-PGDS degrader PROTAC (H-PGDS)-1 and study cedar pollen-induced guinea pig allergic rhinitis.

RS 61756-007 is a selective thromboxane receptor (TP) agonist.

MPX-007, a potent NMDA inhibitor, inhibits GluN2A-containing NMDA receptors expressed in HEK cells with IC50s of 27 nM.

RS-93427-007 is an orally active stable mimetic agent of prostacyclin for the study of mechanisms of atherogenesis.

HB007 is an effective SUMO1 degradation agent that inhibits tumor growth by inducing SUMO1 ubiquitination and degradation, increasing endoplasmic reticulum (ER) stress and ROS production, suitable for cancer research.

G007-LK is a selective inhibitor of TNKS1 and TNKS2, with IC50s of 46 nM and 25 nM, respectively.

ELND007 is a Gamma secretase inhibitor.

AqB007 is a selective blocker of the Aquaporin-1 ion channel conductance, thereby slowing cancer cell migration.

NK007 is a novel anti-SARS-CoV-2 agent with an EC50 value of 30 nM.

XY-06-007, a potent and selective bump-and-hole (B&H) PROTAC BRD4 BD1 L94V degrader, exhibits a DC50, 6 h of 10 nM specifically against BRD4 BD1 L94V without degrading off-targets. It also demonstrates favorable pharmacokinetics for in vivo studies [1].

TUS-007, a modified CANDDY (Chemical knockdown with Affinity aNd Degradation DYnamics) molecule originally derived from a proteasome inhibitor, scarcely affects proteasome activity. It is a potent, orally active degrader of KRAS G12D/V, effective in cell-free chemical knockdown of KRAS G12D/V. Furthermore, TUS-007 has been shown to suppress tumor growth [1].

ADT-007 is an orally active and selective pan-RAS inhibitor with potent anticancer activity.ADT-007 blocks GTP activation of RAS and MAPK/AKT signaling by binding to anucleotide RAS.ADT-007 is used in the study of gastrointestinal cancers.

CXF-007 is a highly effective and selective FGFR4 inhibitor, characterized by an IC 50 value of 7 nM, with demonstrated antitumor activity [1].

Mn007 is a strong inhibitor of bovine pancreatic DNase I, with an IC 50 of 45 μM, achieved through molecular aggregation. Additionally, Mn007 inhibits the growth of S. pyogenes in human whole blood [1].